Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Advancing Bio-purification of Anti-cancer Therapeutic Peptides via Crystallization using Surface Modified Heteronucleants

Project description

Making peptide-based therapies more accessible and affordable

Peptides are small molecules that are emerging as powerful drugs for treating cancers and metabolic disorders as they are highly specific, easy to modify and biocompatible. However, their purification is costly and wasteful. With the support of the Marie Skłodowska-Curie Actions programme, the PetalPure project will develop a crystallisation-based purification process using surface-modified heteronucleants to enhance the ability of these challenging peptides to crystallise. The proposed method provides a more affordable alternative to chromatography, reducing solvent use and the need for expensive resins. By making peptide production more efficient and sustainable, PetalPure aims to improve access to affordable, life-saving treatments.

Objective

Peptides are emerging as next generation therapeutics with a promise of treating cancers and metabolic disorders. This is due to their high specificity, precise targeting, small size, ease of modification, and excellent biocompatibility. Despite the acceleration of peptide drug discovery with >800 drugs in clinical trials, the separation and purification processes remain a challenge, requiring sustainable downstream processing. Thus, there is a need for more efficient purification methods to keep pace with peptide-based drug advancements. PetalPure introduces an innovative crystallization-based purification process using surface-modified heteronucleants to enhance the crystallizability of challenging anti-cancer peptides. This multidisciplinary project involves developing solubility models, size-based peptide classification, heteronucleant selection and modification, crystallization process design, and experimental frameworks for broader application. PetalPure aims to provide a more affordable alternative to chromatographic separation, eliminating the need for expensive resins and reducing solvent consumption and waste, in line with the Sustainable Development Goal (SDG) of Responsible Consumption and Production. Additionally, it will lower the time and cost of peptide manufacturing, facilitating wider access to affordable and effective healthcare, contributing to the SDG of Good Health and Well-being. Prof. Heng, with his extensive experience in biopharmaceutical manufacturing and being a leader in peptide crystallization, is an ideal supervisor for this project. Imperial, with its research excellence and experience with MSCA postdoctoral fellows, will offer a supportive environment for PetalPure. This project will play a pivotal role in making me a leading academic by allowing high-impact research, training on teaching, supervision, and other transferable skills as well as long-term collaboration opportunities with pharmaceutical industry and academics.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Net EU contribution
€ 260 347,92
Address
SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
SW7 2AZ London
United Kingdom
Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data